Some new drugs for advanced prostate cancer patients.
After many years when the treatment landscape for the most common cancer in men, prostate cancer, had been stagnant, four new drugs have recently been approved by the FDA, each of which has been shown to prolong survival:
Enzalutamide (Xtandi), an androgen-receptor signaling inhibitor, was approved by the FDA on 8/31/2012 for the treatment of advanced, castrate-resistant prostate cancer; studies showed that it extended survival in multiple-drug resistant patients by five months.
Abiratarone (Zytiga) is an androgen production down-regulator; it was approved by the FDA last year. It, too, extends survival for patients with advanced prostate cancer who are no longer responding to the usual drugs that lower androgen levels. This drug, as well as Xtandi, are given orally.
The first new standard chemotherapy drug to be approved for the treatment of advanced prostate cancer in more than five years, Cabazitaxel (Jevtana), has also been…
View original post 86 more words